-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $142

Benzinga·07/15/2025 16:41:15
Listen to the news
Canaccord Genuity analyst William Plovanic maintains TransMedics Group (NASDAQ:TMDX) with a Buy and raises the price target from $129 to $142.